The new program will cost between $250 million and $450 million on a pretax basis in the fourth quarter. Merck said it now projects adjusted earnings in the range of $3.28 to $3.32 a share for 2008, and between $3.45 and $3.55 after items are counted.
Analysts surveyed by Thomson Reuters are looking for $3.28 a share on revenue of $24 billion. Pharmaceutical company Wyeth (WYE Quote) also announced its earnings Wednesday morning. Eli Lilly (LLY Quote) is due Thursday.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |
